Search - tctmd.com

Displaying 61 - 80 of 175

Sort: Relevancy | Date

News Daily News

IN.PACT Admiral Data Show No Death Difference at 5 Years for Paclitaxel DCBs vs PTA in Femoropopliteal Disease

L.A. McKeown

January 25, 2019

News Daily News

Industry, Investigators Push Back With Patient-Level Data Showing No Increased Death From Paclitaxel-Based PAD Therapies

L.A. McKeown

January 23, 2019

News Daily News

Slight Advantage for DES Over DCB for In-Stent Restenosis: Updated Meta-analysis

Todd Neale

January 15, 2019

News Features

Top News in Endovascular Therapy: 2018

L.A. McKeown

December 28, 2018

News Daily News

Two Trials Halted in Wake of Study Linking Paclitaxel-Coated Devices to Deaths in PAD

L.A. McKeown

December 17, 2018

News Daily News

Signal of Late Deaths With Paclitaxel-Coated DCBs and Stents for PAD Warrants Urgent Review, Authors Say

L.A. McKeown

December 07, 2018

Presentation ESC 2018

Drug-Coated Balloons for Small Coronary Artery Disease: BASKET-SMALL 2

Presenter: Raban V. Jeger

August 31, 2018

News Conference News ESC 2018

BASKET-SMALL 2: Drug-Coated Balloon Fares Well Against DES for De Novo Small-Vessel Disease

Todd Neale

August 28, 2018

News Industry News

Medtronic Receives FDA Approval for 200mm & 250mm IN.PACT(TM) Admiral(TM) Drug Coated Balloons

June 18, 2018

News Conference News EuroPCR 2018

DES Slightly Edge Out DCBs in Treatment of In-Stent Restenosis: Meta-analysis

Caitlin E. Cox

May 30, 2018

News Conference News EuroPCR 2018

DCBs for CAD in Certain Patients With Large Vessel De Novo Disease? DEBUT Says Yes

Caitlin E. Cox

May 25, 2018

News Daily News

REAL PTX: Head-to-Head DCB, DES Data in PAD Show Trend Favoring Stenting at 36 Months

L.A. McKeown

February 11, 2018

News Industry News

SELUTION™ First-in-Man Study Achieves Primary Endpoint

January 31, 2018

News Industry News

TriReme Medical Reports Negative Late Lumen Loss At 24-Month Angiographic Follow-Up For Chocolate Heart™ Drug-Coated Coronary Balloon

June 22, 2017

News Conference News TCT 2016

RIBS VI: Absorb BVS Safe in In-Stent Restenosis but Fails to Best Xience Metallic Stent

Michael O'Riordan

November 08, 2016

News Conference News VIVA 2016

Longer Term, IN.PACT SFA Trial and Global Registry Continue to Support DCB Therapy as an Option

L.A. McKeown

October 12, 2016

News Conference News VIVA 2016

Long PAD Lesions Respond Well to DCB, but Optimal Patient Selection Still Unclear

L.A. McKeown

September 21, 2016

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for August 2016

Caitlin E. Cox

September 01, 2016

News Daily News

Drug-Coated Balloons Best Suited for In-Stent Restenosis in BMS, not DES

Caitlin E. Cox

August 17, 2016

News Industry News

QT Vascular Receives CE Mark Clearance For Chocolate Heart™, A Novel Drug-Coated Coronary Balloon

July 07, 2016

Advertisement

IN.PACT Admiral Data Show No Death Difference at 5 Years for Paclitaxel DCBs vs PTA in Femoropopliteal Disease

Industry, Investigators Push Back With Patient-Level Data Showing No Increased Death From Paclitaxel-Based PAD Therapies

Slight Advantage for DES Over DCB for In-Stent Restenosis: Updated Meta-analysis

Top News in Endovascular Therapy: 2018

Two Trials Halted in Wake of Study Linking Paclitaxel-Coated Devices to Deaths in PAD

Signal of Late Deaths With Paclitaxel-Coated DCBs and Stents for PAD Warrants Urgent Review, Authors Say

Drug-Coated Balloons for Small Coronary Artery Disease: BASKET-SMALL 2

BASKET-SMALL 2: Drug-Coated Balloon Fares Well Against DES for De Novo Small-Vessel Disease

Medtronic Receives FDA Approval for 200mm & 250mm IN.PACT(TM) Admiral(TM) Drug Coated Balloons

DES Slightly Edge Out DCBs in Treatment of In-Stent Restenosis: Meta-analysis

DCBs for CAD in Certain Patients With Large Vessel De Novo Disease? DEBUT Says Yes

REAL PTX: Head-to-Head DCB, DES Data in PAD Show Trend Favoring Stenting at 36 Months

SELUTION™ First-in-Man Study Achieves Primary Endpoint

TriReme Medical Reports Negative Late Lumen Loss At 24-Month Angiographic Follow-Up For Chocolate Heart™ Drug-Coated Coronary Balloon

RIBS VI: Absorb BVS Safe in In-Stent Restenosis but Fails to Best Xience Metallic Stent

Longer Term, IN.PACT SFA Trial and Global Registry Continue to Support DCB Therapy as an Option

Long PAD Lesions Respond Well to DCB, but Optimal Patient Selection Still Unclear

TCTMD’s Top 10 Most Popular Stories for August 2016

Drug-Coated Balloons Best Suited for In-Stent Restenosis in BMS, not DES

QT Vascular Receives CE Mark Clearance For Chocolate Heart™, A Novel Drug-Coated Coronary Balloon

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content